Fidaxomicin, a nonabsorbed macrocyclic compound, is the first antimicrobial agent approved by the FDA for the treatment of Clostridium difficile infection (CDI) in adults over the last 25 years. It is bactericidal, and its mechanism of action relates to inhibition of a RNA polymerase at a site distinct from where rifamycins interact. Fidaxomicin, 200 milligrams by mouth twice daily, is not inferior to vancomycin, 125 milligrams by mouth 4 times daily, for treatment of CDI as determined by clinical response after 10 days of treatment and is superior to vancomycin for sustained response without recurrence 25 days after treatment completion. These results are a significant advance in the treatment of CDI and herald the development of narrow-spectrum anti-C. difficile agents that relatively spare the indigenous fecal microbiota. Continued vigilance for the development of resistance and unanticipated side affects will be important as the drug is introduced into clinical practice.
The Gram-positive sporulating anaerobe Clostridium difficile has been found to be responsible for as much as 20%-30% of cases of diarrhea associated with antibiotic use [1] . Over the past decade, there have been reports of increasing morbidity and mortality associated with the emergence of a clonal group of C. difficile strains (BI/NAP1/027) associated with global outbreaks that have had higher rates of complications and deaths than previously reported [2] [3] [4] .
In May 2010, the updated guidelines for the treatment of C. difficile infection (CDI) in adults were released and endorsed by both the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America [5] . The guidelines suggest that the initial choice of treatment should be determined based on the severity of illness. Recent studies have shown that patients with severe CDI had significantly better outcomes when treated with oral vancomycin compared with metronidazole [6, 7] . As many as 20%-30% of patients who respond to treatment will have a recurrence up to 8 weeks after completion of treatment, with most of these recurrences occurring within the first 14 days [8] . These rates of recurrence appear to be similar between those treated initially with vancomycin or metronidazole [7, 9, 10] .
Until now, vancomycin has been the only drug that was approved by the US Food and Drug Administration (FDA) for treatment of CDI, although professional societies endorsed the off-label use of metronidazole for mild-to-moderate cases of CDI [5] . In May 2011, the FDA approved the use of fidaxomicin, a new macrocyclic antibiotic for the treatment of CDI in adults. In this article, we review the chemistry, mechanism of action, pharmacokinetics, antimicrobial activity, clinical studies, adverse events, and formulary issues that have been reported with the use of fidaxomicin.
CHEMISTRY
Fidaxomicin represents the first commercially available agent in a new macrocyclic class of antibacterial agents. Like other macrolides, fidaxomicin comprises a large macrocyclic lactone ring. However, unlike the other 14-membered ring macrolides (eg, erythromycin, clarithromycin) and the 15-membered ring macrolide (azithromycin), which bind to the 50S ribosomal subunit and are generally bacteriostatic, fidaxomicin has an 18-membered ring ( Figure 1 ) that has a completely different mode of action and is bactericidal. Fidaxomicin is derived from the fermentation of tiacumicin metabolites from a soil isolate of the actinomycete Dactylosporangium aurantiacum. The drug has a molecular weight of 1058 g/mol, and is metabolized by hydrolysis to form its main metabolite OP-1118 by a presumptive esterase at an unknown site [12] [13] [14] . The antibacterial activity of OP-1118 is at least 8-16 times lower than the activity of fidaxomicin [14] . Fidaxomicin is available as a 200 milligram tablet and is recommended to be given orally twice daily for 10 days with or without food.
MECHANISM OF ACTION
Lipiarmycins are a family of macrocyclic antibiotics, one of which is lipiarmycin A3 (aka tiacumicin B) [13, [15] [16] [17] [18] . Fidaxomicin is composed of stereomerically pure form of R-tiacumicin B, which has an (R)-configuration at the C-19 chiral center [19] . Adding lipiarmycins to growing cultures of Bacillus subtilis results in reduced cellular growth along with a reduction in uracil incorporation during RNA synthesis [20] . This pattern suggests that lipiarmycins specifically inhibit nucleic acid synthesis by impairing the initiation of RNA chain synthesis and transcription [20] . Although the exact molecular mode of action is still being worked out, fidaxomicin acts as a RNA polymerase inhibitor by binding to the DNA template-RNA polymerase (RNAP) complex prior to the formation of the open RNAP-DNA complex in which transcription is initiated (Figure 2A ) [13] . In contrast, the rifamycins block the initiation of RNA synthesis at a later stage by binding to a pocket within the b-subunit of RNAP (RpoB), resulting in allosteric changes that prevent formation of the first phosphodiester bond (r-pathway) or the second bond (b-pathway) in growing RNA chains ( Figure 2B ) [15] .
PHARMACOKINETICS
In the phase IA and IB studies, healthy volunteers were given either a single dose of fidaxomicin followed by a second larger dose or they were given a fixed dose of fidaxomicin for a 10-day period [14] . No fidaxomicin was detected in the urine of subjects in either study. In both phase IA and IB studies, the plasma levels of fidaxomicin were low or near the lower limit of quantification (5 ng/ml), whereas the mean OP-1118 levels were slightly higher, ranging from 11.8 to 33.1 ng/mL depending on the day and time of the sample collection [14] . There was no incremental accumulation of fidaxomicin in the plasma in the multidose study [14] . The combined fecal recovery of fidaxomicin and OP-1118 in the phase IA study was approximately 116.6 6 47.1% of the 200 and 300 milligram oral doses, respectively. Fecal concentration levels of fidaxomicin in the phase IB study were shown to be dose dependent, and rose incrementally as the daily dose increased [14] .
During the phase IIA dose-finding study among patients with clinical CDI, the total plasma levels of fidaxomicin ranged from 5.3 to 84.9 ng/mL, with 88% of patients in the 400 milligram total daily dose having levels below 20 ng/mL. As seen in the previous phase IA/IB studies, the plasma levels of OP-1118 in the 400 milligram total daily dose group (5-402.3 ng/mL) were higher than fidaxomicin, with 94% of patients having levels below 100 ng/mL [12] . In the 13 evaluable patients receiving the 400 milligram total daily dose of fidaxomicin, the mean fecal concentrations of their final day stool samples were measured at 1433 6 975 lg/g for fidaxomicin and 760 6 373 lg/g for OP-1118 [12] . The mean plasma levels of fidaxomicin were [21] . The mean end of therapy fecal concentrations of fidaxomicin was 1225.1 6 759 lg/g [21] .
With mean fecal concentration levels of about 1225 lg/g, and a minimum inhibitory concentration, for which 90% of isolates are susceptible (MIC 90 ) of 0.25 lg/mL, the intracolonic levels are about 5000 times above the MIC 90 [21] . All of the foregoing data suggest that the systemic bioavailability of fidaxomicin is minimal and that the majority of the drug (and its main metabolite OP-1118) remain intracolonic to provide the maximal opportunity to exert its bactericidal activity against C. difficile.
ANTIMICROBIAL ACTIVITY AND RESISTANCE
Fidaxomicin has been called a narrow-spectrum agent with respect to its good activity against C. difficile and relative poor activity against anaerobic gram-negative bacteria that normally populate the colon [22] [23] [24] . In vitro activity of fidaxomicin to representative enteric bacteria is comparable to that of vancomycin (Table 1) . However, in clinical trials of CDI, vancomycin has a much more profound effect on Bacteroides spp. fecal concentrations compared with fidaxomicin [25] . Using culture-independent methodologies, Tannock et al [26] also showed that fidaxomicin had much less effect on the fecal microbiota, particularly clostridial [13] . B, Inhibition of bacterial RNAP by the rifamycins (including rifaximin) occurs at a site in the b-subunit of RNAP that contains an Mg11 ion, resulting in allosteric signals to the active site and preventing formation of the first or second phosphodiester bond in the nascent RNA chain (NTP) [15] .
clusters XIVa and IV (butyrate-producing bacteria that represent a major proportion of the total colonic bacteria) and Bifidobacterium.
In vitro studies against 525 clinical C. difficile isolates from North America, South America, and Europe over a 24-year period have shown the MIC to be in the range of #0.03-1 lg/mL and an MIC 90 of 0.5 lg/mL (Table 2) [27] [28] [29] . In the phase IIA clinical trial, susceptibility of the recovered epidemic BI/NAP1/027 isolates tended to have higher MICs than non-BI/NAP1/027 isolates, but this was not statistically significant [30] .
In the laboratory, when C. difficile isolates were exposed to 4-8 times the MIC of tiacumicin B, the frequency of spontaneous resistance was found to be ,2.8 3 10
28 and similar to that of metronidazole and vancomycin [18] . Similar results have been seen with fidaxomicin [13] . In the second phase III clinical trial, 1 fidaxomicin-treated patient had a C. difficile isolate recovered at baseline and at the end of therapy in which the MIC for fidaxomicin was 0.06 lg/mL [11, 31] . The patient subsequently had a recurrence 6 days after completing treatment, and the strain isolated at that time had an MIC of 16 lg/ml and was associated with a specific RpoB gene (rpoB) mutation (Val-1143-Gly) [11, 31] . Laboratory-derived mutants with increased fidaxomicin MICs (1, 2, and 4 lg/mL) have been associated with mutations in the RNA polymerase b#-subunit gene (rpoC) as well as in the b-subunit gene (rpoB) [32] , but the mutations in rpoB appear to be distinct from those generated by exposure to the rifamycins. Spontaneous lipiarmycin A3-resistant mutants in Mycobacterium tuberculosis (MTB) strains had rpoB gene mutations outside of the hotspot region of rpoB (codons 507-533) where all of the rifampin-resistant MTB mutations were localized [33] and where no cross-resistance to these drugs were noted.
Fidaxomicin and the OP-1118 metabolite exhibit bactericidal activity against C. difficile in vitro, including the laboratoryderived mutants mentioned previously [32] . There also appears to be a significant postantibiotic effect of fidaxomicin [34] . The bacteria continue to be inhibited by the drug, even after its removal for 5.5-10 hours after the last dose of fidaxomicin, compared with vancomycin, which was found to have a postantibiotic effect of 0-1.5 hours [34] .
In summary, there is no evidence for cross-resistance between fidaxomicin and other classes of antibiotics, including the rifamycins, which also act by RNAP inhibition [13, 16] . To date, no clinical isolate with high MIC levels for fidaxomicin (eg, .256 lg/mL) has been reported as was seen for rifampin and rifaximin [35] .
CLINICAL STUDIES

Phase IIA
In the first clinical treatment trial, patients with CDI were randomized to receive 50, 100, or 200 milligrams of fidaxomicin twice daily for 10 days [12] . Patients with more than 12 diarrhea episodes/day, severe abdominal symptoms, a white blood cell (WBC) count of .30 000 cells/mL, toxic megacolon, or concern for life-threatening illness were all excluded [12] . Clinical cure ranged from 71% to 80% in the lower-dosed regimens, and 94% in the group receiving 200 milligrams twice daily [12] . All patients receiving the higher dose had resolution of diarrhea and required no additional treatment. There were no clinical failures in this group, and recurrence of disease was seen in 6.3% (1/16) of patients [12] . Based on these data, the dose regimen of 200 milligrams twice daily was chosen for the subsequent phase III studies.
Phase III
In the first multicenter, double-blind, randomized clinical trial of fidaxomicin versus vancomycin, a total of 629 patients with primary CDI or those with a first recurrence were enrolled [21] . The modified intention to treat (mITT) population (n 5 596) included patients who received at least 1 dose of the study drug, and the per protocol (pp) population (n 5 548) were patients who had received more than 3 days of study drug, were adherent to treatment, and underwent end-of-study evaluation. The primary endpoint was clinical cure at the end of therapy or at the time of withdrawal from the study. The secondary endpoints were CDI recurrence in the 4-week period after end of therapy and global cure. The global cure rate was defined as the resolution of diarrhea without recurrence during follow-up. Patients with life-threatening CDI (WBC count .30,000 cells/mL, temperature .40°C, hypotension, shock, peritoneal signs, or significant dehydration) were excluded. Patients were stratified to mild, moderate, or severe disease based on the frequency of diarrhea and baseline WBC count.
Clinical cures were similar for fidaxomicin (FDX) compared with vancomycin (VAN) in both the mITT (88.2% vs 85.5%, FDX vs VAN) and the pp (92.1% vs 89.8%, FDX vs VAN) groups, and fidaxomicin was considered noninferior for the primary endpoint [21] . There were also no significant differences in the clinical cures between fidaxomicin and vancomycin in the subsequent subgroup analyses by age, location of treatment, initial versus first recurrence, baseline severity, strain type, previous treatment, or failure to respond to metronidazole [21] . There was a trend toward shorter time to resolution of symptoms in the fidaxomicin-treated patients, but the difference was not statistically significant.
Recurrence of CDI as defined by diarrhea and a positive stool toxin assay within 4 weeks of initial cure was significantly less common among fidaxomicin-treated patients compared with vancomycin-treated patients in both the mITT (15.4% vs 25.3%, FDX vs VAN, P 5 .005) and pp groups (13.3% vs 24%, FDX vs VAN, P 5 .004) [21] . This difference in lower rates of recurrence in the fidaxomicin arm also held up in the subgroup analysis for both the mITT and pp groups for patients with a first episode of CDI, outpatient treatment, patients infected with non-BI/NAP1/ 027 C. difficile strains, and patients with severe CDI at baseline. Global cure rates were significantly higher in the fidaxomicintreated patients versus the vancomycin-treated patients in both the mITT (74.6% vs 64.1%, FDX vs VAN, P 5 .006) and pp (77.7% vs 67.1%, FDX vs VAN, P 5 .006) groups [21] .
A second, large phase III trial comparing fidaxomicin and vancomycin (including CDI patients from Europe and North America) has been completed and reported in abstract form [36] . Preliminary results from this trial mirror the results from the first phase III study, confirming the noninferiority of fidaxomicin for initial cure, decreased recurrence rate, and superior global cure or sustained response without recurrence 25 days after treatment completion over vancomycin.
Use of concomitant systemic antibiotics and infection with the BI/NAP1/027 strain negatively influenced cure rates, and concomitant antibiotics also affected recurrence rates and, hence, global cure rates [21, 37, 38] . In an analysis of the combined data from both phase III trials, use of concomitant systemic antibiotics during CDI treatment was associated with a lower cure rates (84.4% vs 92.6%, P , .001) and prolonged time to resolution of diarrhea (97 vs 54 hours, P , .001) compared with those that did not receive concomitant antibiotics during treatment [37] . In addition, concomitant antibiotics at any time (during treatment or during follow-up) resulted in lower global cure rates compared with no concomitant antibiotic use (66% vs 75%, P 5 .005) [37] . Among patients who received concomitant antibiotics, treatment with fidaxomicin resulted in higher cure rates (90% vs 79.4%, P 5 .04) and lower recurrence rates (16.9% vs 29.2%, P 5 .048) compared with treatment with vancomycin [37] . Similar to the effect of concomitant antibiotics, infection with the epidemic BI/ NAP1/027 strain resulted in lower cure rates (86.6% vs 94.3%, P , .001, BI/NAP1/027 vs non-BI/NAP1/027, respectively) [38] . This reduction in cure rates was seen among patients treated with fidaxomicin as well as vancomycin [38] , suggesting no advantage of fidaxomicin over vancomycin for the treatment of patients infected with BI/NAP1/027. The reduction in recurrent CDI rates seen with fidaxomicin was noted primarily among those infected with non-BI/NAP1/027 strains [21] , but multivariate analysis of the combined phase III data did not implicate strain differences in recurrence rates [38] .
ADVERSE EVENTS
The overall safety of fidaxomicin suggests that it is well tolerated in healthy volunteers and patients with CDI. All of the reported side effects in the phase IA/IB studies in healthy volunteers were considered mild, and none of the reported effects were thought to be related to the study drug [14] . Twenty percent of study participants in the phase II CDI trial reported adverse events while taking the study drug, but none of those reported events were deemed related to fidaxomicin [12] .
In the first phase III study, among patients evaluated for safety, there were no significant differences noted between fidaxomicin and vancomycin arms for total adverse events reported (62.3% vs 60.4%, respectively) [21] . None of the patients had their medications discontinued secondary to intolerance or allergic reaction to the study drugs [21] . The fidaxomicin group had more reports of dizziness (4% vs 1.2%, P 5 .04) and rash (3% vs 0.6%, P 5 .03) compared with the vancomycin group, but the investigators felt that this was unrelated to the study drug. Laboratory abnormalities were more frequent in the fidaxomicin group compared with the vancomycin group (4.7% vs 1.2%, P 5 .001), but only 3 of the reported laboratory abnormalities were considered related to fidaxomicin use including hyperuricemia and elevated levels of alanine aminotransferase and aspartate aminotransferase. These laboratory abnormalities returned to normal within 77 days of study entry [21] .
Overall, the most common adverse events reported in the clinical studies with fidaxomicin include nausea, vomiting, gastrointestinal hemorrhage, anemia, and neutropenia [11] . There was no significant difference in the reporting of serious adverse events by organ system between fidaxomicin-and vancomycintreated patients (25% vs 24.1%) [21] .
FORMULARY ISSUES
One of the current challenges that clinicians face is the costly nature of a newly introduced antimicrobial agents. Medications costs to treat CDI can range from $4 to more than $1000 depending on the medication, dose, and duration of treatment. At present, it is proposed that a 10-day course of fidaxomicin will cost over $2000. A cost-benefit analysis will be needed to determine the cost effectiveness of fidaxomicin compared with other available agents.
Based on similar cure rates and lower rates of recurrence compared with vancomycin, fidaxomicin will likely be increasingly used to treat CDI. The simplified twice-daily dosing schedule and favorable safety profile with minimal systemic absorption (and low risk of drug interactions) all make fidaxomicin an attractive treatment option. One of the decisions faced by hospital formularies and reimbursement parties will be which patients will benefit most and to which group will fidaxomicin be restricted.
There are limited published data in humans on the safety of the drug in both pregnancy and breast-feeding patients. There are no data for use of fidaxomicin in children.
In summary, fidaxomicin represents the first agent of a new class of macrocyclic antibiotics and is only the second agent to be approved by the FDA for the treatment of CDI. Compared with vancomycin, fidaxomicin appears to have a less deleterious effect on the indigenous microbiota, and this difference is the most likely explanation for the lower rates of recurrence with fidaxomicin. Although its role in severe, complicated CDI remains unclear, introduction of fidaxomicin into clinical practice comes at a time when the management of CDI and its recurrences pose an increasing challenge to clinicians.
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